NO20062665L - 4-biarylyl-1-fenylazetodon-2-oner - Google Patents

4-biarylyl-1-fenylazetodon-2-oner

Info

Publication number
NO20062665L
NO20062665L NO20062665A NO20062665A NO20062665L NO 20062665 L NO20062665 L NO 20062665L NO 20062665 A NO20062665 A NO 20062665A NO 20062665 A NO20062665 A NO 20062665A NO 20062665 L NO20062665 L NO 20062665L
Authority
NO
Norway
Prior art keywords
biarylyl
img
ones
fenylazetodon
tif
Prior art date
Application number
NO20062665A
Other languages
English (en)
Norwegian (no)
Inventor
Mark G Currie
Eduardo Martinez
John J Talley
Stephen Antonelli
Timothy C Barden
Regina Lundrigan-Soucy
Wayne C Schairer
Jing-Jing Yang
Daniel P Zimmer
Brian Cali
Peter S Yorgey
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc filed Critical Microbia Inc
Publication of NO20062665L publication Critical patent/NO20062665L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062665A 2003-11-10 2006-06-09 4-biarylyl-1-fenylazetodon-2-oner NO20062665L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51869803P 2003-11-10 2003-11-10
US54957704P 2004-03-03 2004-03-03
US59252904P 2004-07-30 2004-07-30
US61400504P 2004-09-28 2004-09-28
PCT/US2004/037715 WO2005047248A1 (en) 2003-11-10 2004-11-10 4-biarylyl-1-phenylazetidin-2-ones

Publications (1)

Publication Number Publication Date
NO20062665L true NO20062665L (no) 2006-08-09

Family

ID=34596124

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062665A NO20062665L (no) 2003-11-10 2006-06-09 4-biarylyl-1-fenylazetodon-2-oner

Country Status (22)

Country Link
US (2) US7320972B2 (pt)
EP (1) EP1682499B1 (pt)
JP (1) JP2007520453A (pt)
KR (1) KR20070050861A (pt)
AT (1) ATE369335T1 (pt)
AU (1) AU2004288822A1 (pt)
BR (1) BRPI0416361A (pt)
CA (1) CA2545058A1 (pt)
CY (1) CY1106982T1 (pt)
DE (1) DE602004008100T2 (pt)
DK (1) DK1682499T3 (pt)
EA (1) EA010026B1 (pt)
ES (1) ES2291974T3 (pt)
HK (1) HK1093974A1 (pt)
IL (1) IL175414A0 (pt)
MA (1) MA28216A1 (pt)
MX (1) MXPA06005106A (pt)
NO (1) NO20062665L (pt)
NZ (1) NZ546940A (pt)
PL (2) PL380414A1 (pt)
PT (1) PT1682499E (pt)
WO (1) WO2005047248A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
WO2006102674A2 (en) * 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
WO2006116499A1 (en) * 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2006121861A2 (en) * 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
JP2008543744A (ja) * 2005-05-09 2008-12-04 マイクロビア インコーポレーテッド 有機金属ベンゼンホスホナートカップリング剤
CN101218213A (zh) * 2005-05-11 2008-07-09 迈克罗比亚公司 制备酚类4-联苯基氮杂环丁烷-2-酮的方法
EP1885694A2 (en) * 2005-05-13 2008-02-13 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
WO2006127893A2 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008057948A2 (en) * 2006-11-01 2008-05-15 Ironwood Pharmaceuticals, Inc. Processes for production of diphenylylazetidin-2-ones and related compounds
US20100069347A1 (en) * 2006-11-02 2010-03-18 Morriello Gregori J Heterocyclyl-substituted anti-hypercholesterolemic compounds
PE20081877A1 (es) 2007-03-06 2008-12-27 Teijin Pharma Ltd Derivado de la 1,4-diarilacetidinona
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
JP5637982B2 (ja) * 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2531511A1 (en) * 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37721A (en) * 1863-02-17 Improvement in hose-couplings
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE50111751D1 (de) * 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
HUP0401501A3 (en) * 2001-09-21 2012-02-28 Schering Corp Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1682117A1 (en) * 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
CN101218213A (zh) * 2005-05-11 2008-07-09 迈克罗比亚公司 制备酚类4-联苯基氮杂环丁烷-2-酮的方法
WO2006127893A2 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds

Also Published As

Publication number Publication date
EP1682499A1 (en) 2006-07-26
HK1093974A1 (en) 2007-03-16
ATE369335T1 (de) 2007-08-15
CA2545058A1 (en) 2005-05-26
DE602004008100T2 (de) 2008-04-30
US7320972B2 (en) 2008-01-22
AU2004288822A1 (en) 2005-05-26
BRPI0416361A (pt) 2007-05-08
PT1682499E (pt) 2007-11-05
PL1682499T3 (pl) 2008-01-31
ES2291974T3 (es) 2008-03-01
EP1682499B1 (en) 2007-08-08
EA200600950A1 (ru) 2006-10-27
MA28216A1 (fr) 2006-10-02
NZ546940A (en) 2008-11-28
DK1682499T3 (da) 2008-01-02
CY1106982T1 (el) 2012-09-26
IL175414A0 (en) 2006-09-05
KR20070050861A (ko) 2007-05-16
WO2005047248A1 (en) 2005-05-26
EA010026B1 (ru) 2008-06-30
DE602004008100D1 (de) 2007-09-20
MXPA06005106A (es) 2007-01-25
JP2007520453A (ja) 2007-07-26
PL380414A1 (pl) 2007-01-22
US20080167255A1 (en) 2008-07-10
US20050209165A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
CY1106982T1 (el) 4-διαρυλυλο-1-φαινυλαζετιδιν-2-ονες
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
TNSN04165A1 (en) Substituted hydroxyethylamines
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
ATE372767T1 (de) Dpp-iv-hemmer
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
HUP0402310A2 (hu) 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
DE602004007808D1 (de) Neue gamma secretase inhibitoren
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE60326819D1 (de) Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
DE602004010680D1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
EP2266971A3 (en) Hiv protease inhibiting compounds
ATE287403T1 (de) 6-phenylbenzonaphthyidine
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse
RU2003118102A (ru) 5`-аминокарбонилфосфонаты d4т-ингибиторы репродукции вируса иммунодефицита человека
DE60021914D1 (de) Triazatrinaphthyrinen und ihre verwendung
RU2004102937A (ru) 1-(пиридинил-2)-2-азолил-1-(фторфенил)этанолы и их применение в качестве фунгицидов
RU2003121213A (ru) Гетероциклические о-дикарбонитрилы
RS20050181A (en) Novel benzonaphthyridines
TH77764B (th) อนุพันธ์ของ 1-(4-เบนซิล-ไพเพอราซิน-1-อิล)-3-เฟนิล-โพรพิโนน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application